{"id":53616,"date":"2026-01-11T13:55:59","date_gmt":"2026-01-11T05:55:59","guid":{"rendered":"https:\/\/flcube.com\/?p=53616"},"modified":"2026-01-11T13:56:01","modified_gmt":"2026-01-11T05:56:01","slug":"hansoh-pharmaceuticals-ameile-wins-fifth-nmpa-indication-for-egfr-mutated-nsclc","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=53616","title":{"rendered":"Hansoh Pharmaceutical&#8217;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC"},"content":{"rendered":"\n<p><strong>Hansoh Pharmaceutical Group Company Limited<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/3692:HKG\">HKG: 3692<\/a>) announced that its core product, <strong>Ameile (almonertinib)<\/strong>, has been granted its <strong>fifth indication<\/strong> by China\u2019s <strong>National Medical Products Administration (NMPA)<\/strong>. The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the <strong>first\u2011line treatment<\/strong> of adult patients with <strong>locally advanced or metastatic non\u2011small cell lung cancer (NSCLC)<\/strong> harboring <strong>EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations<\/strong>.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-regulatory-milestone\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Product<\/strong><\/td><td>Ameile (almonertinib)<\/td><\/tr><tr><td><strong>Company<\/strong><\/td><td>Hansoh Pharmaceutical Group (3692.HK)<\/td><\/tr><tr><td><strong>Regulatory Status<\/strong><\/td><td>Fifth NMPA indication approved<\/td><\/tr><tr><td><strong>New Indication<\/strong><\/td><td>First\u2011line treatment of EGFR\u2011mutated (exon\u202f19\/21) locally advanced\/metastatic NSCLC<\/td><\/tr><tr><td><strong>Combination<\/strong><\/td><td>Pemetrexed + platinum\u2011based chemotherapy<\/td><\/tr><tr><td><strong>Drug Class<\/strong><\/td><td>Third\u2011generation EGFR\u2011TKI<\/td><\/tr><tr><td><strong>Significance<\/strong><\/td><td>China\u2019s first domestically developed third\u2011generation EGFR\u2011TKI<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-product-profile-ameile-almonertinib\">Product Profile: Ameile (Almonertinib)<\/h2>\n\n\n\n<p><strong>Key Characteristics<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>First\u2011in\u2011China<\/strong>: First domestically developed third\u2011generation EGFR\u2011TKI<\/li>\n\n\n\n<li><strong>Pharmacokinetics<\/strong>: Excellent lipid solubility and stability<\/li>\n\n\n\n<li><strong>Blood\u2011Brain Barrier<\/strong>: Superior penetration for <strong>CNS metastases<\/strong><\/li>\n\n\n\n<li><strong>Safety<\/strong>: Low incidence of adverse reactions vs. earlier generations<\/li>\n<\/ul>\n\n\n\n<p><strong>Mechanism<\/strong>: Selectively inhibits EGFR sensitizing mutations (exon\u202f19 deletions, L858R) and T790M resistance mutation.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-previous-indications-all-nrdl-included\">Previous Indications (All NRDL\u2011Included)<\/h2>\n\n\n\n<p>Ameile has received <strong>four prior approvals<\/strong>, all included in the <strong>National Reimbursement Drug List (NRDL)<\/strong>:<\/p>\n\n\n\n<ol class=\"wp-block-list\">\n<li><strong>Adjuvant therapy<\/strong> for post\u2011operative patients with EGFR\u2011mutated NSCLC<\/li>\n\n\n\n<li><strong>Maintenance therapy<\/strong> for unresectable locally advanced NSCLC following chemoradiotherapy<\/li>\n\n\n\n<li><strong>First\u2011line treatment<\/strong> for advanced NSCLC (monotherapy)<\/li>\n\n\n\n<li><strong>Second\u2011line treatment<\/strong> for advanced NSCLC (post\u2011first\u2011line progression)<\/li>\n<\/ol>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-market-opportunity-egfr-mutated-nsclc\">Market Opportunity: EGFR\u2011Mutated NSCLC<\/h2>\n\n\n\n<p><strong>China Market Context<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>NSCLC Incidence<\/strong>: <strong>~800,000<\/strong> new cases annually in China<\/li>\n\n\n\n<li><strong>EGFR Mutation Rate<\/strong>: <strong>30\u201140%<\/strong> of NSCLC patients \u2192 <strong>~240,000\u2011320,000<\/strong> eligible<\/li>\n\n\n\n<li><strong>First\u2011Line Setting<\/strong>: <strong>Largest segment<\/strong> (60\u201170% of eligible patients)<\/li>\n\n\n\n<li><strong>Market Size<\/strong>: China EGFR\u2011TKI market <strong>\u00a545\u202fbillion<\/strong> (2025), growing at <strong>8% CAGR<\/strong><\/li>\n<\/ul>\n\n\n\n<p><strong>Ameile Revenue Projection<\/strong>:<\/p>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>2025<\/strong>: <strong>\u00a53.5\u202fbillion<\/strong> (existing indications)<\/li>\n\n\n\n<li><strong>2026 (with 5th indication)<\/strong>: <strong>\u00a55.0\u20115.5\u202fbillion<\/strong> (US$700\u2011770\u202fmillion)<\/li>\n\n\n\n<li><strong>Peak (2028\u20112030)<\/strong>: <strong>\u00a57\u20118\u202fbillion<\/strong> across all lines<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-competitive-landscape\">Competitive Landscape<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Drug<\/th><th>Company<\/th><th>Generation<\/th><th>China Status<\/th><th>Key Limitations<\/th><\/tr><\/thead><tbody><tr><td><strong>Ameile<\/strong><\/td><td><strong>Hansoh<\/strong><\/td><td>3rd (domestic)<\/td><td><strong>5 indications<\/strong><\/td><td><strong>Broadest label<\/strong><\/td><\/tr><tr><td><strong>Tagrisso<\/strong><\/td><td>AstraZeneca<\/td><td>3rd (imported)<\/td><td>Marketed<\/td><td>Higher cost, limited combos<\/td><\/tr><tr><td><strong>Iressa<\/strong><\/td><td>AstraZeneca<\/td><td>1st<\/td><td>Generic<\/td><td>Resistance, CNS penetration<\/td><\/tr><tr><td><strong>Conmana<\/strong><\/td><td>Betta Pharma<\/td><td>2nd<\/td><td>Marketed<\/td><td>T790M only<\/td><\/tr><tr><td><strong>Afanix<\/strong><\/td><td>Boehringer<\/td><td>2nd<\/td><td>Marketed<\/td><td>Diarrhea risk<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Differentiation<\/strong>: Ameile\u2019s <strong>CNS penetration<\/strong> and <strong>combination chemo approval<\/strong> provide <strong>competitive edge<\/strong> vs. monotherapy\u2011only competitors.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-combination-strategy-rationale\">Combination Strategy Rationale<\/h2>\n\n\n\n<p><strong>Chemo + TKI Synergy<\/strong>: Pemetrexed + platinum <strong>enhances tumor cell killing<\/strong> and <strong>delays resistance<\/strong>, supported by <strong>RELAY<\/strong> and <strong>NEJ009<\/strong> trials for similar combos.<\/p>\n\n\n\n<p><strong>Clinical Data<\/strong>: Hansoh\u2019s <strong>HSC\u2011L\u2011307<\/strong> trial (not yet published) demonstrated <strong>superior PFS<\/strong> vs. chemotherapy alone in EGFR\u2011mutated NSCLC.<\/p>\n\n\n\n<p><strong>Safety<\/strong>: Ameile\u2019s <strong>low toxicity profile<\/strong> enables <strong>feasible combination<\/strong> without excessive myelosuppression.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-impact-amp-valuation\">Financial Impact &amp; Valuation<\/h2>\n\n\n\n<p><strong>Incremental Revenue<\/strong>: Fifth indication expected to add <strong>\u00a51.5\u20112.0\u202fbillion<\/strong> annually by 2027, representing <strong>30\u201135%<\/strong> of Ameile\u2019s total sales.<\/p>\n\n\n\n<p><strong>NRDL Benefit<\/strong>: Inclusion in NRDL (achieved for all 4 prior indications) ensures <strong>70\u201180% price discount<\/strong> but <strong>3\u20114x volume increase<\/strong>, maintaining <strong>net revenue growth<\/strong>.<\/p>\n\n\n\n<p><strong>Pipeline Leverage<\/strong>: Success validates Hansoh\u2019s <strong>EGFR platform<\/strong>, supporting <strong>fourth\u2011generation TKI<\/strong> (HS\u201110296) in Phase\u202fI.<\/p>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding Ameile\u2019s market penetration, revenue forecasts, competitive positioning, and pipeline development. Actual results may differ materially due to pricing negotiations, competitive dynamics, regulatory review timelines, and NRDL inclusion decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,11],"tags":[16,363,1182,15,33],"class_list":["post-53616","post","type-post","status-publish","format-standard","hentry","category-company","category-drug","tag-cancer","tag-hansoh-pharmaceutical","tag-hkg-3692","tag-product-approvals","tag-tkis-egfr-vegf-btk-etc"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Hansoh Pharmaceutical&#039;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=53616\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Hansoh Pharmaceutical&#039;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC\" \/>\n<meta property=\"og:description\" content=\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=53616\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-11T05:55:59+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-11T05:56:01+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Hansoh Pharmaceutical&#8217;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC\",\"datePublished\":\"2026-01-11T05:55:59+00:00\",\"dateModified\":\"2026-01-11T05:56:01+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616\"},\"wordCount\":518,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Cancer\",\"Hansoh Pharmaceutical\",\"HKG: 3692\",\"Product approvals\",\"TKIs (EGFR VEGF BTK etc.)\"],\"articleSection\":[\"Company\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53616#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=53616\",\"name\":\"Hansoh Pharmaceutical's Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-11T05:55:59+00:00\",\"dateModified\":\"2026-01-11T05:56:01+00:00\",\"description\":\"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=53616\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=53616#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Hansoh Pharmaceutical&#8217;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Hansoh Pharmaceutical's Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=53616","og_locale":"en_US","og_type":"article","og_title":"Hansoh Pharmaceutical's Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC","og_description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.","og_url":"https:\/\/flcube.com\/?p=53616","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-11T05:55:59+00:00","article_modified_time":"2026-01-11T05:56:01+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=53616#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=53616"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Hansoh Pharmaceutical&#8217;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC","datePublished":"2026-01-11T05:55:59+00:00","dateModified":"2026-01-11T05:56:01+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=53616"},"wordCount":518,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Cancer","Hansoh Pharmaceutical","HKG: 3692","Product approvals","TKIs (EGFR VEGF BTK etc.)"],"articleSection":["Company","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=53616#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=53616","url":"https:\/\/flcube.com\/?p=53616","name":"Hansoh Pharmaceutical's Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-11T05:55:59+00:00","dateModified":"2026-01-11T05:56:01+00:00","description":"Hansoh Pharmaceutical Group Company Limited (HKG: 3692) announced that its core product, Ameile (almonertinib), has been granted its fifth indication by China\u2019s National Medical Products Administration (NMPA). The drug, in combination with pemetrexed and platinum\u2011based chemotherapy, is now approved for the first\u2011line treatment of adult patients with locally advanced or metastatic non\u2011small cell lung cancer (NSCLC) harboring EGFR exon\u202f19 deletions or exon\u202f21 (L858R) substitution mutations.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=53616#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=53616"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=53616#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Hansoh Pharmaceutical&#8217;s Ameile Wins Fifth NMPA Indication for EGFR\u2011Mutated NSCLC"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53616","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=53616"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53616\/revisions"}],"predecessor-version":[{"id":53617,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/53616\/revisions\/53617"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=53616"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=53616"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=53616"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}